Bactrinol

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bactrinol

Quick Facts

Property Description
Active ingredient Sulphamethoxazole and Trimethoprim
Form Fixed-dose combination (Synthetic)
Pharmacological class Antimicrobial, Antibiotic (Sulfonamide/Antifolate combo)
Common use Treatment and prevention of bacterial and protozoal infections
Origin Synthetic chemical preparation

What is Bactrinol, and What Type of Medicine is It?

Bactrinol is a widely recognized trade name for the synthetic, prescription-only drug known generically as Co-trimoxazole, which is formally classified as a potent antimicrobial agent. This medication is distinct because it is a fixed-dose combination product, incorporating two active components: Sulphamethoxazole (a Sulfonamide antibiotic) and Trimethoprim (an Antifolate antibiotic).

This dual-action design has been clinically recognized for its high efficacy against common pathogens, supported by extensive pharmacological studies. The combination of Sulphamethoxazole and Trimethoprim is the definitive feature of the drug, known worldwide by the INN Co-trimoxazole, and is also commonly marketed under popular trade names such as Bactrim and Septra. As an antimicrobial, this drug is used to treat and prevent many bacterial infections and is widely cost-affordable.

Composition and Available Forms of Co-trimoxazole

The therapeutic power of Bactrinol stems from the two active ingredients, Sulphamethoxazole and Trimethoprim, which are always combined in a precise, synergistic ratio, reflecting their purely synthetic origin. This fixed ratio is essential to ensure the desired sequential metabolic blockade.

The medicine is supplied in several key dosage forms to accommodate the necessary route of administration, including tablets for oral administration and a sterile solution for intravenous infusion. Furthermore, the availability of an oral suspension provides a suitable liquid format, facilitating accurate administration, particularly for pediatric patients.

General Purpose and Mechanism: The Synergistic Antimicrobial Effect

The general function of Co-trimoxazole is primarily bactericidal—it is designed to kill targeted microorganisms, offering a stronger effect than agents that only suppress growth. This superior action results from the powerful synergistic effect of the dual ingredients.

The mechanism works by blocking sequential steps in the bacteria’s vital metabolic processes, specifically targeting the essential production of folic acid that is necessary for the organisms to grow and reproduce. The drug is effective against numerous bacterial, fungal, and protozoal pathogens, confirming that the combined components provide broad-spectrum utility against various microbial sources of infection.

Regulatory References

  1. NIH StatPearls: Trimethoprim Sulfamethoxazole
  2. NIH StatPearls

What side effects are possible with Bactrinol?

Possible side effects and safety information

The official safety profile of Bactrinol (Co-trimoxazole) is organized by frequency and the body systems affected, as documented in regulatory sources.

Frequency-Classified Adverse Reactions and Affected Systems

Adverse reactions are formally categorized to provide context on their expected occurrence:

  • Very Common (ge 1/10): Increased potassium levels in the blood (Hyperkalaemia), classified under metabolism disorders.
  • Common (ge 1/100 to <1/10): Headache, rash, and gastrointestinal disturbances such as nausea and diarrhea, in addition to fungal overgrowth.
  • Uncommon and Very Rare classifications cover a broader range of reactions, including severe systemic and organ effects.

Documented effects are reported across multiple System-Organ Classes (SOCs), notably the Skin and Subcutaneous Tissue, Gastrointestinal, Blood and Lymphatic System, Hepatic, and Renal systems.

Serious Adverse Reactions

Although classified as Very Rare, regulatory documents explicitly list potentially fatal adverse reactions. These include Severe Cutaneous Adverse Reactions (SCARs) such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), severe blood disorders (e.g., agranulocytosis, aplastic anaemia), and fulminant hepatic necrosis.

Population-Specific and Duration-Related Constraints

The medicine is contraindicated in specific patient populations, including infants less than two months of age and patients with severe hepatic or renal insufficiency. Older adults are noted as being more susceptible to serious adverse reactions, including severe rash. Safety information specifies that the highest risk for SCARs is typically within the first weeks of treatment, and regular blood counts are advisable for patients receiving long-term therapy.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents state that any suspected overdose of Bactrinol (Co-trimoxazole) requires immediate emergency medical attention. Manifestations of acute overdose may include severe symptoms such as nausea, vomiting, confusion, dizziness, and fever. More serious clinical signs documented in labeling include blood in the urine, yellowing of the skin or eyes (jaundice), or severe electrolyte abnormalities such as hyperkalaemia.

When severe outcomes occur, such as a seizure, circulatory collapse, or loss of consciousness, emergency services must be contacted immediately, as mandated by regulatory authorities.

Administration of Leucovorin (Folinic Acid) is required to counteract the serious, delayed complication of bone marrow depression, which is officially described as a risk following acute toxicity. Supportive care involves symptomatic treatment, maintenance of adequate fluid intake to ensure urinary output, and hospital monitoring that requires measuring plasma Sulphamethoxazole concentrations. Official labeling notes that elderly patients, particularly those with existing kidney or liver impairment, face a higher susceptibility to serious effects in an overdose scenario.

Therapeutic Uses of Bactrinol

What Bactrinol Treats: Main Uses and Benefits

Bactrinol (Co-trimoxazole) is commonly used to manage infections across several therapeutic domains where symptoms relate to heightened physiological activity caused by susceptible bacteria and parasites. As an antimicrobial, the drug is used to treat and prevent many bacterial infections.

Treating Acute Symptom Burdens and Systemic Distress

This medication is commonly used to help with groups of symptoms that may appear suddenly in the urinary tract, middle ear, lower respiratory system, and gastrointestinal tract. This includes conditions presenting with symptoms like painful urination, acute ear pain, severe watery diarrhea, or worsened cough and breathing difficulties. The therapeutic benefit is to address the source of infection, which provides supportive relief that helps patients cope more steadily with these acute symptomatic episodes.

“It is applied in addressing symptom clusters that may become intense or disruptive and interfere with daily comfort.”

Essential Prophylaxis and Treatment

Bactrinol is applied in clinical settings that involve acute or unstable symptom patterns, especially for opportunistic infections in immunocompromised individuals. This includes providing essential long-term support to reduce the risk of developing life-threatening conditions like Pneumocystis Jirovecii Pneumonia (PJP) and Toxoplasmosis. The drug is relevant for managing symptomatic discomfort across therapeutic areas, including uncomplicated UTIs, Acute Otitis Media, Traveler's Diarrhea, Shigellosis, and PJP.


Quick Fact: Relief for Infection-Driven Symptoms
Symptom Domain Focus Urinary, Respiratory, Gastrointestinal, and Opportunistic Infections
Benefit Category Provides support that helps ease the overall symptom burden
Use Scenario Commonly used when symptoms intensify and supportive relief is needed

Regulatory References

  1. NIH StatPearls overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Bactrinol (Co-trimoxazole)

The eligibility for using Bactrinol is strictly defined by regulatory guidelines, focusing on absolute contraindications and population-specific restrictions.

Contraindicated Populations

Bactrinol must not be used in the following groups, as stated in official product labeling:

  • Infants less than 2 months of age.
  • Individuals with a known hypersensitivity to Sulphamethoxazole, Trimethoprim, or any sulfonamide-derivative.
  • Patients with severe hepatic damage or severe renal insufficiency where drug monitoring is not possible.
  • Patients with megaloblastic anemia due to folate deficiency.

Age and Physiological Restrictions

Population Group Regulatory Status
Children Eligible from 2 months of age and older under labeled conditions.
Older Adults Eligible, but use requires particular care due to increased susceptibility to adverse reactions and potential organ decline.
Pregnancy Not recommended during the first and late third trimesters.

Condition-Based Limitations

Use is not recommended for patients with acute porphyria. Individuals with moderate renal impairment or existing folate deficiency are eligible but require specific modifications or close monitoring as defined in the official prescribing information.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Bactrinol (Co-trimoxazole: Sulfamethoxazole and Trimethoprim) defines specific restrictions and clinically significant interactions based on two primary domains: pharmacokinetic interference and additive pharmacodynamic effects.

Contraindicated and Restricted Combinations

Co-administration is formally restricted with Dofetilide, as the Trimethoprim component significantly increases its plasma concentration, posing a serious risk of cardiac toxicity. Use is also contraindicated with Clozapine due to a heightened risk of neutropenia.

Pharmacokinetic Interactions

Bactrinol components interfere with the clearance of several medicines, leading to increased plasma exposure. Sulfamethoxazole inhibits the metabolism of Warfarin, potentiating its anticoagulant effect. Trimethoprim inhibits the renal tubular secretion of Digoxin and Lamivudine, increasing their circulating levels. The half-life of Phenytoin is also prolonged through inhibited metabolism.

Pharmacodynamic and Specific Effects

The drug creates additive pharmacological effects when combined with certain medicines. There is an increased risk of severe hyperkalaemia when co-administered with ACE inhibitors, ARBs, or potassium-sparing diuretics. It also has additive antifolate effects with Methotrexate, enhancing toxicity. This profile requires the restriction of co-administered Folinic acid (Leucovorin), as it directly antagonizes the antimicrobial efficacy. An increased risk of thrombocytopenia is specifically noted in elderly patients receiving Thiazide diuretics.

Mechanism of Action

How Bactrinol Works

Bactrinol operates through distinct biochemical pathways, engaging mechanisms that collectively influence dysregulated cellular processes. This action is primarily centered on modulating key enzymatic and receptor-mediated signaling sequences.


Modulation of Key Enzymatic Signaling

This domain involves the drug's effect on enzyme-mediated pathways that govern essential physiological responses. Bactrinol initiates signaling sequences by modifying early molecular steps, thereby reducing mediator activity and influencing the net activity of cellular communication.


Engagement of Receptor-Mediated Feedback Loops

The drug acts within systems where specific receptors or transmitters dominate, modulating intrinsic pathway feedback mechanisms. This pathway adjustment leads to resulting physiological adjustments by affecting signal transduction rates within specific systems.

Dosage and Administration Information

How to Use Bactrinol

Bactrinol (Co-trimoxazole) is prescribed under strict official guidelines that govern its administration, dosing, and duration of use. The medicine is supplied for two official routes of administration: Oral (as tablets or suspension) and Intravenous (IV) Infusion (as a sterile solution).


Official Dosing and Frequency

The standard adult dose for acute infections is typically 800 mg Sulphamethoxazole / 160 mg Trimethoprim (one Double Strength tablet or equivalent) taken every 12 hours. However, high-dose regimens, such as those used for treating Pneumocystis Jirovecii Pneumonia (PJP), require a higher total daily dose divided and administered every 6 to 8 hours.

Administration Factor Official Instruction Summary
Standard Frequency Every 12 hours for acute conditions.
IV Administration Must be diluted immediately and infused slowly over 60 to 90 minutes.
Hydration Should be taken with plenty of fluids (e.g., a full glass of water).
Duration Varies widely: 5 days (e.g., Traveler's Diarrhea) to 3 months (e.g., Nocardiosis).

Population-Specific Adjustments

Official labeling mandates dose modification for patients with impaired kidney function. For individuals with a creatinine clearance (CrCl) of 15-30 mL/min, the dose must be half the standard amount. The drug is generally not recommended for infants under 2 months of age and is contraindicated below this age. Oral forms may be taken with some food or drink to minimize potential gastrointestinal upset, but tablets should not be crushed or chewed.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Bactrinol

This section provides a factual overview of the research and studies conducted on Bactrinol (trimethoprim and sulfamethoxazole combination). Findings describe group patterns observed in the studies, and research does not determine whether an individual will respond similarly.


Evidence for Use in Pneumocystis jirovecii Pneumonia (PJP) Treatment

Research for PJP has involved short-term Randomized Controlled Trials (RCTs) and comparative studies. These studies examined patient populations, including adults and children two months of age and older, often within immunocompromised groups. Outcomes related to systemic or functional imbalance were evaluated, such as organism clearance, survival, and general patterns of adverse events that researchers monitored in the context of research for PJP.

Studies reported measurements of patient survival, microbiological clearance rates, and documented general safety patterns over the treatment period. Research limitations include the potential for study protocols to reflect older clinical standards, and data for certain subgroups remain insufficient.


Evidence for Use in Severe or Complicated Urinary Tract Infections (UTIs)

Bactrinol was studied for complicated UTIs using Randomized Controlled Trials and comparative clinical trials. Research examined outcomes related to systemic or functional imbalance in adults and pediatric patients diagnosed with UTIs caused by specified susceptible bacteria. Studies monitored how symptoms evolved, reporting findings related to bacterial clearance measurements and outcomes related to physical discomfort, such as fever.

Long-term effects are not fully established for sustained microbiological cure or impact on future infection risk. The applicability of existing evidence is challenged by increasing bacterial resistance rates, which can lead to variability in trial relevance.


What is Still Uncertain About Bactrinol Research

Research highlights what is known and what is still uncertain across the evidence landscape. Evidence is limited regarding the long-term effects of Bactrinol beyond short-term follow-up. Follow-up durations were often limited, meaning that a complete understanding of outcomes reflecting daily functioning over extended time intervals is not fully established.

Key Studies & References

  1. Low-dose trimethoprim-sulfamethoxazole treatment for Pneumocystis pneumonia: a systematic review and meta-analysis
  2. Clinical Practice Guideline by Infectious Diseases Society of America (focusing on cUTI and resistance trends)

Frequently Asked Questions (FAQ)

Common questions about Bactrinol (FAQ)


Q: How long does it typically take for a person to notice the effects of Bactrinol?

Official information indicates that the concentration of the medicine in the blood usually peaks within 1 to 4 hours after an oral dose is taken. For specific infections, clinical guidance often recommends monitoring for improvement within 48 to 72 hours of starting treatment.


Q: Are there any specific foods or drinks that should be avoided when taking Bactrinol?

While there are no broad dietary restrictions, regulatory documents state that Bactrinol is to be taken with plenty of fluids, such as a full glass of water. It is important to know that consuming foods high in potassium simultaneously with the medicine may increase the risk of hyperkalaemia (high potassium levels) in at-risk patients.


Q: How long does Bactrinol stay in the body after the last use?

The active components of Bactrinol have different half-lives, which is the time it takes for half of the drug to leave the body. Sulphamethoxazole and Trimethoprim both average about 8 to 10 hours. Due to this, small amounts of the drug may still be detectable in the bloodstream for up to a full day after the final administration.


Q: Is Bactrinol affected by drinking alcohol?

Some official drug information suggests that combining the sulphamethoxazole component with alcohol may potentially cause side effects like fast heartbeats, flushing, or nausea in sensitive people. Official drug information suggests discussing alcohol consumption with a healthcare provider.


Q: Is it known if Bactrinol is safe to use during pregnancy?

Official product labeling states that Bactrinol is generally not recommended during the first trimester or near the time of delivery. Its use may be considered in the second trimester if the potential benefit is determined to outweigh any risk, particularly if safer alternatives have not been effective.


Q: Is there a maximum time a person can be on Bactrinol?

Regulatory documents describe treatment durations that range from a few days up to several months for specific long-term conditions. The official safety profile indicates that patients receiving long-term therapy should have regular blood counts monitored, but a universal maximum treatment time is not formally defined.


Q: What is the expected duration of the medicine's effect?

Bactrinol is typically dosed to be taken every 12 hours. This administration schedule is based on the drug's half-life and is intended to ensure that a steady and effective concentration of the medicine is maintained in the body to combat the target infection.


Q: Why do some people say Bactrinol helps with issues that aren't its main use?

Regulatory documents strictly specify the infections and conditions for which Bactrinol has received official approval. Uses that are not specified in the official product labeling are considered off-label and have not been formally evaluated or recommended by government health authorities.


Q: Can Bactrinol affect the results of standard lab tests?

Yes, regulatory information indicates that Bactrinol can potentially impact the results of certain laboratory tests. It may lead to a reversible increase in blood levels of potassium and creatinine, and can also cause abnormalities in complete blood counts or elevated liver enzymes.


Q: Is Bactrinol considered a 'strong' medicine?

Official documentation describes Bactrinol as a potent antimicrobial agent. It is noted for its synergistic (combined) action from two components, resulting in a bactericidal effect designed to kill target microorganisms. Official documents also note that the drug is associated with a need for monitoring due to the risk of rare, serious adverse reactions.


Q: What are the most commonly reported side effects people mention online?

Officially classified Common adverse reactions—those occurring in up to 1 in 10 people—include headache, rash, and gastrointestinal disturbances such as nausea and diarrhea. An increase in blood potassium levels (Hyperkalaemia) is classified as a Very Common side effect.


Q: Is there any public research available about the long-term use of Bactrinol?

Official regulatory summaries of clinical research often note that follow-up durations were limited, and a full understanding of outcomes over extended time intervals is not fully established. However, studies evaluating long-term use for certain preventative purposes do exist.


Q: Can a person take Bactrinol if they have mild kidney issues?

Official prescribing information requires specific dose adjustments for individuals with moderate renal impairment (a certain level of reduced kidney function). The dose must be reduced to half the standard amount in this population. The drug is not recommended for those with severe renal insufficiency.


Q: Are there known interactions between Bactrinol and herbal supplements?

Official drug labels detail interactions with specific prescription medicines. Since Bactrinol has antifolate effects (meaning it works by blocking a form of folic acid), information regarding any herbal supplement that contains or affects folic acid is typically reviewed by a healthcare provider.


Q: Is it normal to have a slight headache when first starting Bactrinol?

Headache is officially classified as a Common side effect. While the timing of the onset of common effects like headache is not generalized, official safety data notes that the risk for certain more serious skin reactions is highest during the first few weeks of starting treatment.


Q: Is it true that taking Bactrinol with certain vitamins can change how it works?

Yes. The drug's mechanism is based on blocking the body's use of folate. Regulatory information states that the medicine's efficacy is directly reduced by Folinic acid (Leucovorin) and that it has additive antifolate effects when taken with medicines like Methotrexate.


Q: When should someone stop taking Bactrinol?

Bactrinol is intended to be used for the full prescribed duration. Official regulatory documents specify that the drug must be discontinued immediately if a patient develops certain serious adverse reactions, such as a severe rash or blood disorders.


Q: Does Bactrinol need to be taken at a specific time of day?

The standard dose for acute infections is usually taken every 12 hours to maintain consistent levels in the bloodstream. While the exact time of day may vary, the 12-hour interval is critical. The drug may be taken with food or drink to help minimize stomach upset.


Q: Are there any warnings about using Bactrinol if you have heart problems?

Official documents describe serious warnings related to heart health. It may increase the risk of severe hyperkalaemia (high potassium) when used with certain blood pressure or heart failure medicines. It is also restricted for use with the heart rhythm drug Dofetilide due to a risk of serious cardiac toxicity.


Q: Does Bactrinol interact with hormonal birth control?

Authoritative public health bodies classify most broad-spectrum antibiotics, including this type, as generally having no restriction for use with combined hormonal contraceptives. Such use is typically reviewed by a healthcare provider.


Q: Are there any specific lab monitoring requirements for people using Bactrinol?

Yes. Official safety information recommends regular blood counts for patients receiving long-term or high-dose therapy. Monitoring of kidney function (creatinine) and serum potassium levels is also advised, particularly for patients with underlying kidney issues or other risk factors.


Q: What information is available about the effectiveness of Bactrinol in clinical trials?

Clinical trials reviewed for approval examined specific outcomes like organism clearance, survival, and the incidence of adverse events in study groups. The research findings describe overall group patterns related to approved uses, such as in complicated urinary tract infections and certain types of pneumonia.


Q: What does the research say about using Bactrinol for less common indications?

The official research evidence summaries included in regulatory documents focus exclusively on the drug's approved uses and indications. Studies concerning less common or uses not approved by regulatory bodies are not summarized in the official product information.


Q: How quickly do potential side effects usually appear after taking Bactrinol?

Regulatory information notes that the risk for the most severe skin reactions (SCARs) is highest during the first few weeks of treatment. The onset time for common side effects, such as gastrointestinal upset or headache, may occur shortly after starting the medicine.


Q: Are there any restrictions on activity while using Bactrinol?

Yes. Bactrinol is known to cause photosensitivity, which is an increased sensitivity to light. Official warnings advise patients to avoid unnecessary sun exposure and to use protective measures, such as clothing and sunscreen, to help reduce the risk of sunburn or rash.


Q: Why are there different strengths of Bactrinol available?

Different strengths are supplied to allow healthcare providers to facilitate proper dosing for various purposes. These include accommodating the differences between adult and pediatric patients and providing specific higher-dose regimens required for treating certain severe infections.


Q: What kind of studies were done to get Bactrinol approved?

The drug's approval was based on research that included short-term Randomized Controlled Trials (RCTs) and comparative clinical studies. These trials monitored patient outcomes, microbiological clearance, and general adverse event patterns for the specific conditions the drug is approved to treat.


Q: What are the main reasons people stop taking Bactrinol?

Official guidelines require the medicine to be stopped if a patient develops certain Serious Adverse Reactions (SCARs), such as a severe, widespread rash or serious blood disorders. The drug is also stopped naturally when the patient completes the full prescribed course of treatment.


Q: Do people often report feeling dizzy after taking Bactrinol?

Dizziness is not classified as one of the most common (Very Common or Common) adverse reactions in official regulatory documents. However, it is a symptom that may be reported in the context of a potential mild allergic reaction.

How should Bactrinol be stored and disposed of?

How to Store and Dispose of Bactrinol

Official regulatory documents define specific conditions to maintain the stability and integrity of Bactrinol (Co-trimoxazole).

Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Protection Protect from light and keep the container tightly closed.
Form Specific The oral suspension formulation must not be refrigerated.
Child Safety Keep out of the sight and reach of children.

Disposal Instructions

Unused or expired medication must not be flushed down a toilet or poured into a drain. Disposal should follow approved local or federal guidelines, such as utilizing a community drug take-back program or following the FDA-recommended sealed household trash method.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bactrinol found in:

A-Z Index: